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In 1999 it was known that the major demonstrated effect of COX-2s, compared with non-steroidal anti-inflammatory drugs (NSAIDs), was a reduction in shallow 'endoscopic' ulcers which are clinically unimportant. 3 The beneficial effect on serious, complicated ulcers was very much less. In patients with rheumatoid arthritis and no other risk factors, the annual risk of developing a complication related to NSAID use is only 0.4%. COX-2s could possibly reduce this to 0.2% (likely to be expressed as a 50% reduction for marketing purposes). In this group it would be necessary to treat 500 patients to prevent one complicated ulcer. In younger, healthier individuals the 'number needed to treat' would be even higher. 3 Yet in Australia more than 50% of the patients prescribed COX-2s were under 65. 4 Many doctors gained the false impression that selective drugs were also less likely than conventional NSAIDs to have adverse effects on blood pressure and the kidneys. This view was also held by some key opinion leaders -people who always have a major influence on prescribing patterns and, for this reason, 
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There seems to be a glamour about anything new, despite the absence of long-term safety information when a drug is first approved. Of course the industry designs and interprets trials to maximise favourable outcomes. Of course it puts the best possible spin on its marketing messages, but doctors should be smart enough to see through the hype. They need to know that when a drug first appears on the market only limited safety data are available and long-term outcomes, both good and bad, can only emerge with time and appropriately designed, prospective safety studies. It is well established that most prescribers obtain the majority of their information from the pharmaceutical industry and they therefore need more training in how to evaluate the information and what questions to ask drug representatives. 5 The National Prescribing Service in a recent publication suggests that we should think about what is not known rather than what is known about new drugs. 6 Medical schools and postgraduate colleges must take more responsibility for training students and young doctors about assessing new drugs. This involves more than just an extrapolation of evidence-based medicine. We cannot complacently offload all blame onto government regulators and industry.
Rofecoxib is by no means the first drug to be summarily removed from the market. Cerivastatin and mibefradil suffered a similar fate, in both cases because of fatal toxicity due to interactions with other drugs. There are also many examples of new drugs which have had significant safety warnings added to their product information within a few years of marketing.
There is no merit in being among the first to prescribe a new drug whatever the pressures from patients and drug companies.
It has been well said that 'For all newly-licensed drugs, confidence about safety can only be provisional'. 1 It is essential that both prescribers and consumers grasp this fundamental fact.
